1. Home
  2. MDWD vs EVC Comparison

MDWD vs EVC Comparison

Compare MDWD & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • EVC
  • Stock Information
  • Founded
  • MDWD 2000
  • EVC 1996
  • Country
  • MDWD Israel
  • EVC United States
  • Employees
  • MDWD N/A
  • EVC N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • EVC Broadcasting
  • Sector
  • MDWD Health Care
  • EVC Industrials
  • Exchange
  • MDWD Nasdaq
  • EVC Nasdaq
  • Market Cap
  • MDWD 195.2M
  • EVC 226.5M
  • IPO Year
  • MDWD 2014
  • EVC 2000
  • Fundamental
  • Price
  • MDWD $19.47
  • EVC $2.00
  • Analyst Decision
  • MDWD Strong Buy
  • EVC
  • Analyst Count
  • MDWD 2
  • EVC 0
  • Target Price
  • MDWD $35.00
  • EVC N/A
  • AVG Volume (30 Days)
  • MDWD 83.0K
  • EVC 151.2K
  • Earning Date
  • MDWD 11-25-2025
  • EVC 11-05-2025
  • Dividend Yield
  • MDWD N/A
  • EVC 9.52%
  • EPS Growth
  • MDWD N/A
  • EVC N/A
  • EPS
  • MDWD N/A
  • EVC N/A
  • Revenue
  • MDWD $19,858,000.00
  • EVC $396,704,000.00
  • Revenue This Year
  • MDWD $21.39
  • EVC $64.06
  • Revenue Next Year
  • MDWD $23.01
  • EVC N/A
  • P/E Ratio
  • MDWD N/A
  • EVC N/A
  • Revenue Growth
  • MDWD N/A
  • EVC 25.34
  • 52 Week Low
  • MDWD $14.14
  • EVC $1.58
  • 52 Week High
  • MDWD $22.51
  • EVC $2.73
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 66.30
  • EVC 26.78
  • Support Level
  • MDWD $17.72
  • EVC $2.20
  • Resistance Level
  • MDWD $18.54
  • EVC $2.14
  • Average True Range (ATR)
  • MDWD 0.62
  • EVC 0.08
  • MACD
  • MDWD 0.22
  • EVC -0.03
  • Stochastic Oscillator
  • MDWD 86.01
  • EVC 2.62

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: